Jen Cao

June 12, 2023

Jen has over 15 years of experience in cancer research working with small and large molecules. At Pheast, Jen leads the Translational Science team that develops the biomarker strategies to drive the preclinical and clinical development of our investigational cancer therapeutics through all phases of the portfolio. Previously, Jen served as a biomarker scientist at Forty Seven Inc. and Gilead, where she led translational efforts for CD47 and SIRPA clinical programs. Prior to those roles, she worked at Pharmacyclics (AbbVie-Sunnyvale) developing novel therapeutics in the hematology/oncology space. Jen completed her postdoctoral training at Stanford University and received a Ph.D. in Molecular Genetics from the University of Toronto.